H-Leu-Ser-Lys-Leu-OH 

H-Leu-Ser-Lys-Leu-OH (LSYL) is a latency-associated peptide at the amino terminus of LAP, with inhibitory effect on TGF-β1 activation. H-Leu-Ser-Lys-Leu-OH, binding with KRFK (HY-P3970), can block the signal transduction of TGF-β1, and prevent the progression of hepatic damage and fibrosis^[1].

TGF-β1^[1]

H-Leu-Ser-Lys-Leu-OH (LSKL) also blocks the activation of TGF-b1 by TSP-1, and decreases the activation of TGF-b1 by the KRFK peptide^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

H-Leu-Ser-Lys-Leu-OH (LSKL) (100 μg/0.5 mL; i.p.; daily for 4 weeks, accompanied with DMN) protects dimethylnitrosamine (DMN)-treated (10 mg/kg; i.p.; 3 consecutive days a week for 4 weeks) rats from liver atrophy. H-Leu-Ser-Lys-Leu-OH also prevents the progression of hepatic damage and fibrosis^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

459.58

C₂₁H₄₁N₅O₆

162559-45-7

LSKL

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Kondou H, et al. A blocking peptide for transforming growth factor-beta1 activation prevents hepatic fibrosis in vivo. J Hepatol. 2003 Nov;39(5):742-8.  [Content Brief]